Driven to help researchers further understand COVID-19, VALUENEX aims to provide insights by exploring COVID-19 related public research documents using unique big data visualization methodologies.

ACCESS

ACADEMICVALUENEX WebsiteJune 25, 2020PHARMACEUTICAL, HEALTHCARE

AbbVie's purchase of Allergan expands patent scope | IAM

AbbVie’s $63 billion bid for Allergan has just received ﬁnal approval from the European Commission and is now awaiting word from the US Federal Trade Commission (FTC), which is still reviewing the pending transaction. The tie-up, as covered by IAM, has been described as a short-term solution for AbbVie which is preparing for the loss of exclusivity of its key brand Humira in 2023.

ACCESS

M&AVALUENEX WebsiteOctober 6, 2019PHARMACEUTICAL

Presentation on Confirming M&A Sustainability

Analyzing effective investment volumes with IP synergy indices. A look at technological synergy of major pharmaceutical companies and their acquisitions, and determining investment value.

ACCESS

STRATEGY, M&AVALUENEX WebsiteOctober 5, 2019PHARMACEUTICAL

Sanofi eyes more M&A as deals drive increase in IP portfolio quality | IAM

Sanofi announced a $3.4 billion deal to purchase US biotech company Principia Biopharma. It’s the third-largest pharmaceutical acquisition of 2020 and the company’s second big ticket deal since Paul Hudson joined as CEO in September 2019. The former Novartis executive has made his priorities at Sanofi clear: cut costs and invest in innovative - and lucrative - medicines.

ACCESS

M&A, IPVALUENEX WebsiteOctober 4, 2019PHARMACEUTICAL

Nanoparticle Technology: 15 Years Since the National Nanotechnology Initiative (NNI)

One of the signature nanotechnology research areas is nanoparticles. Much R&D is performed by scaling particles down to the nanoscale, through which researchers are able to observe behavior that differs from that of bulk materials, including quantum behaviors.

ACCESS

VALUENEX WebsiteSeptember 26, 2019CHEMICAL, PHARMACEUTICAL